The term of the collaboration agreement.

No definition available.

Name:	urgn_CollaborationAgreementTerm
Namespace Prefix:	urgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The expiration term of the license agreement.

+ References

No definition available.

+ Details

Name:	urgn_LicenseAgreementExpirationTerm
Namespace Prefix:	urgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum amount to be paid for certain clinical developments and regulatory milestones under the license agreement.

+ References

No definition available.

+ Details

Name:	urgn_LicenseAgreementMaximumPayableForCertainClinicalDevelopmentAndRegulatoryMilestones
Namespace Prefix:	urgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The maximum amount of to be paid upon achievement of certain commercial milestones.

+ References

No definition available.

+ Details

Name:	urgn_LicenseAgreementMaximumPayableForCertainCommercialMilestones
Namespace Prefix:	urgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage of net sales of licensed products to be paid as royalties under the license agreement.

+ References

No definition available.

+ Details

Name:	urgn_LicenseAgreementRoyaltyPercentageOfNetSalesOfLicensedProducts
Namespace Prefix:	urgn_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash outflow for the license agreement.

+ References

No definition available.

+ Details

Name:	urgn_PaymentsForLicenseAgreement
Namespace Prefix:	urgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=urgn_AgenusIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=urgn_MDAndersonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Note 13 - License and Collaboration Agreements (Details Textual) - USD ($) $ in Millions	1 Months Ended		9 Months Ended
	Jan. 31, 2021	Nov. 30, 2019	Sep. 30, 2022
Agenus Inc. [Member]
Payments for License Agreement		$ 10
License Agreement, Maximum Payable for Certain Clinical Development and Regulatory Milestones		115
License Agreement, Maximum Payable for Certain Commercial Milestones		$ 85
License Agreement, Expiration Term (Year)		15 years
Agenus Inc. [Member] \| Minimum [Member]
License Agreement, Royalty, Percentage of Net Sales of Licensed Products		14.00%
Agenus Inc. [Member] \| Maximum [Member]
License Agreement, Royalty, Percentage of Net Sales of Licensed Products		20.00%
MD Anderson [Member]
Collaboration Agreement, Term (Year)	3 years
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross			$ 2